Basic Information
RNALocate ID: | RLID:11001774 |
RNA Symbol: | hsa-miR-141-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-141-3p |
RNA ID: | miRBase:MIMAT0000432 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001783 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:01001784 | P-body | HeLa cells | 28488892 |
RLID:11001768 | Exosome | Human milk | 28688106 |
RLID:11001769 | Exosome | Pulmonary epithelial cell line (BEAS-2B) | 31520698 |
RLID:11001770 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11001771 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001772 | Exosome | Renal cancer cells | 21670082 |
RLID:11001773 | Exosome | Brain tissue | 23382797 |
RLID:11001775 | Microvesicle | Seminal plasma | 23539611 |
RLID:21000268 | Cytoplasmic stress granule | HeLa cells | 28488892 |
RLID-D:11000082 | Exosome | Breast milk|Colon tissue|Seminal fluid | |
RLID-D:11000360 | Microvesicle | Colon cancer cell line (LIM1863)|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-141-3p | Splenic marginal zone lymphoma | MNDR-E-MI-13652 |
MNDR | hsa-miR-141-3p | Renal fibrosis | MNDR-E-MI-13653 |
MNDR | hsa-miR-141-3p | Oral squamous cell carcinoma | MNDR-E-MI-13654 |
MNDR | hsa-miR-141-3p | Large cell neuroendocrine cancer | MNDR-E-MI-13655 |
MNDR | hsa-miR-141-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-13656 |
MNDR | hsa-miR-141-3p | Ovarian clear cell carcinoma | MNDR-E-MI-13657 |
MNDR | hsa-miR-141-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-13658 |
MNDR | hsa-miR-141-3p | Lymphoma | MNDR-E-MI-13659 |
MNDR | hsa-miR-141-3p | Lymphoma non-hodgkin | MNDR-E-MI-13660 |
MNDR | hsa-miR-141-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-13661 |
MNDR | hsa-miR-141-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-13662 |
MNDR | hsa-miR-141-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-13663 |
MNDR | hsa-miR-141-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-13664 |
MNDR | hsa-miR-141-3p | Her2-receptor positive breast cancer | MNDR-E-MI-13665 |
MNDR | hsa-miR-141-3p | Breast cancer luminal | MNDR-E-MI-13666 |
MNDR | hsa-miR-141-3p | Dermatomyositis | MNDR-E-MI-13667 |
MNDR | hsa-miR-141-3p | Prostate cancer | MNDR-E-MI-13668 |
MNDR | hsa-miR-141-3p | Gastric cancer | MNDR-E-MI-13669 |
MNDR | hsa-miR-141-3p | Gastric lymphoma | MNDR-E-MI-13670 |
MNDR | hsa-miR-141-3p | Alzheimer disease | MNDR-E-MI-13671 |
MNDR | hsa-miR-141-3p | Sickle cell anemia | MNDR-E-MI-13672 |
MNDR | hsa-miR-141-3p | Bladder cancer | MNDR-E-MI-13673 |
MNDR | hsa-miR-141-3p | Esophageal carcinoma | MNDR-E-MI-13674 |
MNDR | hsa-miR-141-3p | Dysautonomia familial | MNDR-E-MI-13675 |
MNDR | hsa-miR-141-3p | Head and neck cancer | MNDR-E-MI-13676 |
MNDR | hsa-miR-141-3p | Huntington disease | MNDR-E-MI-13677 |
MNDR | hsa-miR-141-3p | Chorea | MNDR-E-MI-13678 |
MNDR | hsa-miR-141-3p | Cardiovascular disease | MNDR-E-MI-13679 |
MNDR | hsa-miR-141-3p | Lung cancer | MNDR-E-MI-13680 |
MNDR | hsa-miR-141-3p | Endometrial cancer | MNDR-E-MI-13681 |
MNDR | hsa-miR-141-3p | Parkinson disease | MNDR-E-MI-13682 |
MNDR | hsa-miR-141-3p | Breast cancer | MNDR-E-MI-13683 |
MNDR | hsa-miR-141-3p | Cancer | MNDR-E-MI-13684 |
MNDR | hsa-miR-141-3p | Thyroid cancer | MNDR-E-MI-13685 |
MNDR | hsa-miR-141-3p | Pituitary neoplasms | MNDR-E-MI-13686 |
MNDR | hsa-miR-141-3p | Pancreatic cancer | MNDR-E-MI-13687 |
MNDR | hsa-miR-141-3p | Melanoma | MNDR-E-MI-13688 |
MNDR | hsa-miR-141-3p | Rectum adenocarcinoma | MNDR-E-MI-13689 |
MNDR | hsa-miR-141-3p | Nephroblastoma | MNDR-E-MI-13690 |
MNDR | hsa-miR-141-3p | Colon cancer | MNDR-E-MI-13691 |
MNDR | hsa-miR-141-3p | Ischemic attack transient | MNDR-E-MI-13692 |
MNDR | hsa-miR-141-3p | Colon adenocarcinoma | MNDR-E-MI-13693 |
MNDR | hsa-miR-141-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-13694 |
MNDR | hsa-miR-141-3p | Familial ovarian cancer | MNDR-E-MI-13695 |
MNDR | hsa-miR-141-3p | Prostate adenocarcinoma | MNDR-E-MI-13696 |
MNDR | hsa-miR-141-3p | Kidney neoplasms | MNDR-E-MI-13697 |
MNDR | hsa-miR-141-3p | Endometrial endometrioid carcinoma | MNDR-E-MI-13698 |
MNDR | hsa-miR-141-3p | Carcinoma ductal breast | MNDR-E-MI-13699 |
MNDR | hsa-miR-141-3p | Glioblastoma | MNDR-E-MI-13700 |
MNDR | hsa-miR-141-3p | Glioma | MNDR-E-MI-13701 |
MNDR | hsa-miR-141-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-13702 |
MNDR | hsa-miR-141-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-13703 |
MNDR | hsa-miR-141-3p | Epilepsy temporal lobe | MNDR-E-MI-13704 |
MNDR | hsa-miR-141-3p | Osteosarcoma | MNDR-E-MI-13705 |
MNDR | hsa-miR-141-3p | Liposarcoma | MNDR-E-MI-13706 |
MNDR | hsa-miR-141-3p | Breast carcinoma | MNDR-E-MI-13707 |
MNDR | hsa-miR-141-3p | Liver neoplasms | MNDR-E-MI-13708 |
MNDR | hsa-miR-141-3p | Choriocarcinoma | MNDR-E-MI-13709 |
MNDR | hsa-miR-141-3p | Uterine cancer | MNDR-E-MI-13710 |
MNDR | hsa-miR-141-3p | Cervical adenocarcinoma | MNDR-E-MI-13711 |
MNDR | hsa-miR-141-3p | Gastric adenocarcinoma | MNDR-E-MI-13712 |
MNDR | hsa-miR-141-3p | Cervical squamous cell carcinoma | MNDR-E-MI-13713 |
MNDR | hsa-miR-141-3p | Pituitary adenoma | MNDR-E-MI-13714 |
MNDR | hsa-miR-141-3p | Lung squamous cell carcinoma | MNDR-E-MI-13715 |
MNDR | hsa-miR-141-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-13716 |
MNDR | hsa-miR-141-3p | Lung adenocarcinoma | MNDR-E-MI-13717 |
MNDR | hsa-miR-141-3p | Adrenocortical carcinoma | MNDR-E-MI-13718 |
MNDR | hsa-miR-141-3p | Thyroid carcinoma | MNDR-E-MI-13719 |
MNDR | hsa-miR-141-3p | Ovarian carcinoma | MNDR-E-MI-13720 |
MNDR | hsa-miR-141-3p | Bladder urothelial carcinoma | MNDR-E-MI-13721 |
MNDR | hsa-miR-141-3p | Carcinoma renal cell | MNDR-E-MI-13722 |
MNDR | hsa-miR-141-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-13723 |
MNDR | hsa-miR-141-3p | Clear cell renal cell carcinoma | MNDR-E-MI-13724 |
MNDR | hsa-miR-141-3p | Biliary tract cancer | MNDR-E-MI-13725 |
MNDR | hsa-miR-141-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-13726 |
MNDR | hsa-miR-141-3p | Cholangiocarcinoma | MNDR-E-MI-13727 |
MNDR | hsa-miR-141-3p | Lung small cell carcinoma | MNDR-E-MI-13728 |
MNDR | hsa-miR-141-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-13729 |
MNDR | hsa-miR-141-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-13730 |
MNDR | hsa-miR-141-3p | Breast invasive carcinoma | MNDR-E-MI-13731 |
MNDR | hsa-miR-141-3p | Hepatocellular carcinoma | MNDR-E-MI-13732 |
MNDR | hsa-miR-141-3p | Familiar ovarian carcinoma | MNDR-E-MI-13733 |
MNDR | hsa-miR-141-3p | B-cell lymphoma | MNDR-E-MI-13734 |
MNDR | hsa-miR-141-3p | Rheumatoid arthritis | MNDR-E-MI-13735 |
MNDR | hsa-miR-141-3p | Ulcerative colitis | MNDR-E-MI-13736 |
MNDR | hsa-miR-141-3p | Burkitt lymphoma | MNDR-E-MI-13737 |
MNDR | hsa-miR-141-3p | Crohn disease | MNDR-E-MI-13738 |
MNDR | hsa-miR-141-3p | Psoriasis | MNDR-E-MI-13739 |
MNDR | hsa-miR-141-3p | Skin cutaneous melanoma | MNDR-E-MI-13740 |
MNDR | hsa-miR-141-3p | Skin melanoma | MNDR-E-MI-13741 |
MNDR | hsa-miR-141-3p | Acute myelogenous leukemia | MNDR-E-MI-13742 |
MNDR | hsa-miR-141-3p | Colorectal cancer | MNDR-E-MI-13743 |
MNDR | hsa-miR-141-3p | Nasopharyngeal carcinoma | MNDR-E-MI-13744 |
MNDR | hsa-miR-141-3p | Nasopharynx carcinoma | MNDR-E-MI-13745 |
MNDR | hsa-miR-141-3p | Multiple myeloma | MNDR-E-MI-13746 |
MNDR | hsa-miR-141-3p | Ovarian epithelial cancer | MNDR-E-MI-13747 |
MNDR | hsa-miR-141-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-13748 |
MNDR | hsa-miR-141-3p | Uterine cervical neoplasms | MNDR-E-MI-13749 |
MNDR | hsa-miR-141-3p | Ependymoma | MNDR-E-MI-13750 |
MNDR | hsa-miR-141-3p | Nasopharyngeal cancer | MNDR-E-MI-13751 |
MNDR | hsa-miR-141-3p | Prostatic neoplasms | MNDR-E-MI-13752 |
MNDR | hsa-miR-141-3p | Epstein-barr virus infections | MNDR-E-MI-13753 |
MNDR | hsa-miR-141-3p | Brain injury chronic | MNDR-E-MI-13754 |
MNDR | hsa-miR-141-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-13755 |
MNDR | hsa-miR-141-3p | Pituitary acth hypersecretion | MNDR-E-MI-13756 |
MNDR | hsa-miR-141-3p | Breast cancer her3+ negative | MNDR-E-MI-13757 |
MNDR | hsa-miR-141-3p | Low grade dysplastic nodule | MNDR-E-MI-13758 |
MNDR | hsa-miR-141-3p | Renal childhood neoplasms | MNDR-E-MI-13759 |
MNDR | hsa-miR-141-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-13760 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ACVR2B | Homo sapiens | RR00039524 |
TOP